Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Co-Diagnostics Blasted 21% Higher on Thursday

TheMotleyFool

0 0

Why Co-Diagnostics Blasted 21% Higher on ThursdayPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png

The roller-coaster-like trajectory that has been Co-Diagnostics' (NASDAQ: CODX) stock price climbed another hill on Thursday. The healthcare-testing specialist's shares closed over 21% higher on the day, due largely to news of a fresh patent awarded to the company.

Co-Diagnostics announced that its CoPrimer diagnostics platform, which underpins testing products -- like its popular-for-obvious-reasons Logix Smart for COVID-19 -- has been granted a patent in South Korea. This bolsters the intellectual-property protection of CoPrimer, which received a U.S. patent in 2018.

Image source: Getty Images.

Source Fool.com

Like: 0

CODX

Share